Stock DIVISLAB DIVI'S LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Divi's Laboratories Limited

Equities

DIVISLAB

INE361B01024

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 05:13:47 26/04/2024 pm IST 		5-day change 1st Jan Change
4,016 INR +4.49% Intraday chart for Divi's Laboratories Limited +9.39% +2.88%
26/04 Weak March Quarter Earnings Weigh Down Indian Equities on Friday MT
25/04 Divi's Laboratories Plans Up To INR7 Billion Investment to Boost Capacity MT

Business Summary

Divi's Laboratories Limited is specialized in the development and manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.

Net sales by source of revenue break down into product sales (97.9%) and service sales (2.1%).

At the end of March 2020, the group has 2 production sites located in India.

Number of employees: 8,433

Sales per Business

INR in Million2022Weight2023Weight Delta
Active Pharmaceutical Ingredients and Intermediates
100.0 %
89,598 100.0 % 77,675 100.0 % -13.31%

Sales per region

INR in Million2022Weight2023Weight Delta
Europe
41.0 %
28,801 32.1 % 31,873 41.0 % +10.66%
United States
23.8 %
20,047 22.4 % 18,466 23.8 % -7.89%
Asia
13.4 %
7,981 8.9 % 10,412 13.4 % +30.47%
India
12.6 %
10,378 11.6 % 9,756 12.6 % -6.00%
Americas
4.7 %
18,929 21.1 % 3,676 4.7 % -80.58%
Rest of the World
4.5 %
3,462 3.9 % 3,492 4.5 % +0.88%

Managers

Managers TitleAgeSince
Kiran Satchandra Divi CEO
 Chief Executive Officer 46 10/01/10
Murali Krishna P. Divi FOU
 Founder 73 12/90/12
Kishore Babu Lingamneni DFI
 Director of Finance/CFO 74 20/94/20
Srinivasa Rao P. CTO
 Chief Tech/Sci/R&D Officer 59 01/90/01
Ramesh Babu M. CTO
 Chief Tech/Sci/R&D Officer 58 01/90/01
K. Subba Rao ADM
 Chief Administrative Officer 60 01/94/01
L. Ramesh Babu CTO
 Chief Tech/Sci/R&D Officer 71 20/09/20
M. Satish Choudhury CMP
 Compliance Officer - 19/19/19
S. Devendra Rao BRD
 Director/Board Member 62 10/02
Nilima Motaparti BRD
 Director/Board Member 42 01/12/01

Members of the board

Members of the board TitleAgeSince
Murali Krishna P. Divi FOU
 Founder 73 12/90/12
Kiran Satchandra Divi CEO
 Chief Executive Officer 46 10/01/10
Kanteti Venkata Krishna Seshavataram BRD
 Director/Board Member - 23/14/23
Venkata Ramana Nimmagadda BRD
 Director/Board Member 66 26/94/26
Nilima Motaparti BRD
 Director/Board Member 42 01/12/01
S. Devendra Rao BRD
 Director/Board Member 62 10/02
Ramesh B. V. Nimmagadda CHM
 Chairman - 27/17/27
Ganapaty Seru BRD
 Director/Board Member 71 22/17/22
Sunaina Singh BRD
 Director/Board Member 68 28/19/28
Kosaraju Veerayya Chowdary BRD
 Director/Board Member 69 04/20/04

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 265,468,580 126,724,585 ( 47.74 %) 0 47.74 %

Shareholders

NameEquities%Valuation
Kiran Satchandra Divi
20.34 %
54,000,000 20.34 % 2 225 M ₹
Nilima Motaparti
20.34 %
54,000,000 20.34 % 2 225 M ₹
SBI Funds Management Ltd.
7.867 %
20,883,207 7.867 % 861 M ₹
Life Insurance Corporation of India (Investment Portfolio)
5.696 %
15,121,752 5.696 % 623 M ₹
Swarna Latha Divi
5.274 %
14,000,000 5.274 % 577 M ₹
Divis Biotech Pvt Ltd.
3.014 %
8,000,000 3.014 % 330 M ₹
Murali Krishna P. Divi
2.850 %
7,567,000 2.850 % 312 M ₹
Axis Asset Management Co. Ltd.
1.738 %
4,612,715 1.738 % 190 M ₹
UTI Asset Management Co. Ltd. (Investment Management)
1.263 %
3,353,729 1.263 % 138 M ₹
Norges Bank Investment Management
1.208 %
3,206,823 1.208 % 132 M ₹

Company contact information

Divi's Laboratories Ltd.

Divi Towers Cyber Hills, Gachibowli

500032, Hyderabad

+91 40 6696 6300

http://www.divislabs.com
address Divi's Laboratories Limited(DIVISLAB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Divi's Laboratories Limited

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
4,016 INR
Average target price
3,442 INR
Spread / Average Target
-14.29%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
DIVI'S LABORATORIES LIMITED Stock Divi's Laboratories Limited
+2.88% 12.78B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DIVISLAB Stock
  4. Company Divi's Laboratories Limited